Oluseyi Adeniyi

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutated -Metastatic Castrate Resistant Prostate Cancer.

M. Anscher, K. Goldberg, R. Pazdur, 2020, The oncologist.

An Overview of Genomic Biomarker Use in Cardiovascular Disease Clinical Trials

I. Zineh, Jielin Sun, M. Pacanowski, 2019, Clinical pharmacology and therapeutics.

Characterization of Flagellin-Functionalized Liposomes as a Vaccine Carrier and Adjuvant.

Oluseyi Adeniyi, 2015 .

PathFX provides mechanistic insights into drug efficacy and safety for regulatory review and therapeutic development

Rebecca Racz, Anuradha Ramamoorthy, Tianyun Liu, 2018, PLoS Comput. Biol..

Regulatory news: Nulibry (fosdenopterin) approved to reduce the risk of mortality in patients with molybdenum cofactor deficiency type A: FDA approval summary

J. Filie, Hylton V. Joffe, Sheila Farrell, 2021, Journal of inherited metabolic disease.

Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018

M. Pacanowski, A. Ramamoorthy, Hobart L Rogers, 2020, Clinical and translational science.